Docusign (NASDAQ:DOCU) Azioni

DOCUSIGN INC

DocuSign

Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in 2018.

Docusign

Lululemon

Equities

DOCU

GIII

LULU

MANU

Reazioni opposte del mercato ai risultati societari. A fare la differenza non sono gli utili, ma le previsioni per il futuro.

I 5 titoli da tenere d&#39;occhio oggi: crolli, rialzi e sorprese

UltaBeautyGreenwood,,Indiana, - ,United,States,-,June,16,2020:,Beauty

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

ULTA

Analisi pre-market svela opportunità nascoste nel mercato azionario: quali settori guideranno la crescita odierna? Occasione da non perdere.

Wall Street ottimista: questi 5 titoli potrebbero esplodere oggi

Brookdale Reports June 2025 Occupancy Rise: Month-End Consolidated Rate Hits 82.2%, Up 230 bps YoY And 70 bps Sequentially

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) with a Buy and maintains $30 price target.

Price Target

Analyst Ratings

IBRX

D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target

HC Wainwright &amp; Co. analyst Kevin Dede downgrades Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) from Buy to Neutral.

Downgrades

Core Scientific, Inc. - Class A Common Stock

CORZ

HC Wainwright & Co. Downgrades Core Scientific to Neutral

BKNG moves up 1.2% after TradePulse Alert on down day for broad market
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/07203611/Screenshot-2025-07-07-at-4.33.22%E2%80%AFPM-974x1024.png" alt="" class="wp-image-15429" /></figure>
Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:41 AM on July 7th, a significant trading signal occurred for Booking Holdings Inc., (BKNG) as it demonstrated a Power Inflow at a price of $5749.69. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Booking's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Booking's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for BKNG,<a href="https://benzinga.grsm.io/register174"> Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_July2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_July2025</a>
which are responsible for parts of the data within this article.
After Market Close UPDATE:
The price at the time of the Power Inflow was $5749.69. The returns on the High price ($5819.01) and Close price ($5815.92) after the Power Inflow are respectively 1.2% and 1.1%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your appetite for risk.
Past performance is not indicative of future results

Technicals

Opinion

Signals

BKNG

Booking Holdings Stock Up 1.2% After Key Trading Signal

Chardan Capital analyst James McIlree maintains Cleanspark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) with a Buy and maintains $20 price target.

CLSK

Chardan Capital Maintains Buy on Cleanspark, Maintains $20 Price Target

TD Bank Launches Generative AI Virtual Assistant To Boost TD Securities Productivity

D. Boral Capital analyst Jason Kolbert upgrades Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) from Hold to Buy and announces $20 price target.

Upgrades

ARTL

D. Boral Capital Upgrades Artelo Biosciences to Buy, Announces $20 Price Target

GRMN

Garmin Smartwatches Adds Turn-By-Turn Directions With Google Maps In Connect IQ Store

WIIM

PROK

ProKidney shares are trading higher after the company reported statistically and clinically significant topline results from its Phase 2 REGEN-007 trial evaluating Rilparencel in patients with chronic kidney disease and diabetes.

<ul>
<li>Honeywell continues to simplify and optimize its business as part of a portfolio evaluation initiated in early 2024</li>
<li>Following the planned separations, Honeywell will become a pure-play automation business focused on building automation, process automation and technologies and industrial automation</li>
<li>Industry veteran Jim&nbsp;Masso appointed to lead Honeywell's process automation business</li>
</ul>

Honeywell To Explore Strategic Alternatives For Productivity Solutions And Services And Warehouse And Workflow Solutions Businesses Ahead Of 2026 Breakup

Willis, a WTW business (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>), has launched <a href="https://www.globenewswire.com/Tracker?data=DcKyKNR-bIdG6TNxWBtaZWNSwIF1uTnJHz4Ui2PY2z15k6BHu7X-KdmJsr2XqARpEkoLQFRDoEtnE7No9jo7SVddHi_PsezPaqAPXSV5wd4YEaFCRmivxB8o9Hkp4s5QP_aJ8EqhtCI_l4uNhc9pDQ==">‘Undercover'</a>, a new $200 million facility, combining coverage for a range of geopolitical exposures faced by cargo owners worldwide.
Developed by Willis in a joint proposition with specialist insurer, Markel, Undercover offers a unique approach to the risk transfer of cargo, war on land, terrorism, political violence and confiscation coverage, with sections of coverage selected based on the individual needs of the client. This single-facility approach minimizes coverage gaps and reduces the likelihood of claims disputes, as well as removing the need to establish the motivation for a claim.
In challenging times of political instability, Undercover offers certainty of cover to cargo owners. It also provides protection from fluctuating insurance costs when country risk ratings change, as cargo cover is frequently provided on a global basis.

New WTW-Markel Insurance Plan Offers Tailored Coverage for War, Terror, and Confiscation Threats

United Homes Group Reports Q2 2025 Preliminary Results: Net New Orders Down 5.9%, Closings Down 10.1%, Starts Up 2.9% Year-Over-Year

MASS

908 Devices Launches VipIR, Industry-First 3-in-1 Handheld Analyzer With Integrated FTIR, Raman, and Smart Spectral Processing for Field Chemical ID

Larimar Therapeutics, Inc. (Larimar) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the publication of two peer-reviewed articles highlighting nonclinical data on the therapeutic potential, pharmacology, and mechanism of action of nomlabofusp as a novel frataxin (FXN) protein replacement therapy designed to address the underlying cause of Friedreich's ataxia (FA). These data were included in the briefing package reviewed by the U.S. Food and Drug Administration (FDA) in support of potentially using skin FXN concentrations as a reasonably likely surrogate endpoint (RLSE) for Larimar's registrational program seeking accelerated approval for nomlabofusp.
The articles, now available online, are titled:
<ul>
<li>"Pharmacokinetics and Pharmacodynamics of Nomlabofusp in Non‑clinical Studies of Friedreich's Ataxia" (<a href="https://link.springer.com/article/10.1208/s12248-025-01093-y">link</a>)</li>
<li>"Nomlabofusp, a Fusion Protein of Human Frataxin and a Cell Penetrant Peptide, Delivers Mature and Functional Frataxin into Mitochondria" (<a href="https://link.springer.com/article/10.1208/s12248-025-01054-5">link</a>)</li>
</ul>

Larimar Therapeutics, Inc. - Common Stock

LRMR

Larimar Highlights Data for Rare Disease Drug Nomlabofusp in FDA Briefing

Driven by retailer demand for greater food safety and transparency, cheese producers worldwide are lining up to join the rapidly growing ReposiTrak Traceability Network
ReposiTrak (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRAK#NYSE">TRAK</a>), the world's largest food traceability and regulatory compliance network, leveraging its established inventory management and out-of-stock reduction SaaS platform, is proud to add 31 cheese suppliers to the queue of companies joining the ReposiTrak Traceability Network&#xAE; (RTN). These companies will efficiently exchange intricate, FDA-required Key Data Elements (KDEs) for each Critical Tracking Event (CTE) in their supply chains, with the goal of meeting the growing traceability demands of their retail customers.

TRAK

ReposiTrak Adds 31 Cheese Suppliers To Queue Of Companies Joining ReposiTrak Traceability Network

JinkoSolar Commissions 21.6 MWh Energy Storage Systems With Distributed Energy Infrastructure Under SMART Program

Biotech

General

BCLI

BrainStorm Cell Therapeutics Acknowledges FDA Consideration Of Citizen Petition Requesting New Review Of Data Supporting NurOwn; Says Will Continue With Planned Phase 3b Trial

Today, IBM (NYSE:&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2864195-1&amp;h=964409748&amp;u=http%3A%2F%2Fwww.ibm.com%2Finvestor&amp;a=IBM">IBM</a>)&nbsp;revealed IBM Power11, the next generation of IBM&#xAE; Power&#xAE; servers. Redesigned with innovations across its processor, hardware architecture, and virtualization software stack, Power11 is designed to deliver the availability, resiliency, performance, and scalability enterprises demand, for seamless hybrid deployment on-premises or in IBM Cloud.
&nbsp;
Organizations across industries have long run their most mission-critical, data-intensive workloads on IBM Power, most notably those within the banking, healthcare, retail, and government spaces. Now, enterprises face an onslaught of new technologies and solutions as they transition into the age of AI. IDC found that one billion new logical applications are expected by 2028, and the proliferation of these systems poses new complexities for companies.1 IBM built Power11 to deliver simplified, always-on operations with hybrid cloud flexibility for enterprises to maintain competitiveness in the AI era.
Power11 is designed to be the most resilient server in the history of the IBM Power platform, with 99.9999% of uptime.2 Together with zero planned downtime for system maintenance3 and less than one-minute guaranteed ransomware threat detection with IBM Power Cyber Vault,&nbsp;4 Power11 sets a new bar for business continuity, addressing both planned and cyber-incident-related downtime.&nbsp;
For the first time ever, the Power11 general availability will simultaneously include high-end, mid-range, and entry servers as well as IBM Power Virtual Server in IBM Cloud. IBM Power Virtual Server offers a fast path to the cloud for Power workloads, and is certified as a hyperscaler platform for <a href="https://www.ibm.com/cloud/rise-with-sap">RISE with SAP</a>.&nbsp; Power11 will also be the first IBM Power server to support the IBM Spyre Accelerator, IBM's system-on-a-chip available Q4 2025 that is purpose-built for today's AI-intensive inference workloads. Available across IBM's enterprise systems portfolio, including Power11, <a href="https://www.ibm.com/products/z17">IBM z17</a>, and <a href="https://www.ibm.com/products/linuxone-5">LinuxONE 5</a>, Spyre will deliver advanced AI acceleration to help organizations scale AI across hybrid cloud environments.
With support for autonomous operations, Power11 delivers intelligent performance gains that reduce complexity and improve workload efficiency. Power11 offers up to 55% better core performance compared to Power95 and has up to 45% more capacity with higher core counts in entry and mid-range systems compared to Power10.6 &nbsp;This upgraded performance means that with Power11, enterprises are positioned to achieve enhanced flexibility and security, to transform their enterprise processes through automation.

IBM Unveils Power11 Servers With AI Acceleration and 99.9999% Uptime for Enterprise Workloads

Aeva's 4D LiDAR Technology Enables Advanced Intrusion Detection Near Perimeters
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aeva.com%2F&amp;esheet=54287123&amp;newsitemid=20250708943634&amp;lan=en-US&amp;anchor=Aeva&amp;index=1&amp;md5=ea0334bd3a85954c558815636a582429">Aeva</a>&#xAE; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NASDAQ">AEVA</a>), a leader in next-generation sensing and perception systems, today announced that Sandia National Laboratories has completed its evaluation phase of Aeva's 4D LiDAR technology. Following the previously announced selection of Aeva's technology, Sandia is planning to test Aeva's technology at a U.S. nuclear reactor site to evaluate its performance to enhance security and assess threat detection capabilities. These include for potential intrusions in the perimeter areas of the facility, such as water intakes that are important for safe reactor operation.

AEVA

Aeva Says Sandia National Laboratories Completes Evaluation Phase Of Aeva's 4D LiDAR Technology

Redwire Completes Integration of Hammerhead Spacecraft for ESA Tech Demo Mission, Marks Second Platform Milestone at Belgium Facility This Summer

Press Releases

Identity Fraud Costs Organizations an Average of $7 Million Annually, Says New Research From Docusign and Entrust

Docusign tops Newsweek's list of the Most Trustworthy Software and Telecommunications Companies in America 2025

New Docusign Partner Program to Drive Business Success in the Era of Intelligent Agreement Management

Docusign Ushers in a New Era of AI Contract Agents to Transform Business

Cognizant Expands Partnership with Docusign to Enhance Customer Support and Drive Digital Transformation

Docusign Appoints Michael Adams as New Chief Information Security Officer

Docusign CLM Connector for Coupa Certified as Coupa Total Spend Management Platform Ready

Docusign Announces Timing of First Quarter Fiscal 2026 Earnings Conference Call

Fintech

Docusign Announces First Quarter Fiscal 2026 Financial Results; Announces $1.0 Billion Increase to Share Repurchase Program

Docusign launching six personality-packed signature styles for ESIGN Act's 25th anniversary

Comments

Docusign

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO